(Total Views: 642)
Posted On: 06/19/2017 8:12:38 PM
Post# of 72447
Do not disagree.
My point is that they are sitting with an approved drug and no suitor, at least for the US market. Why? The drug has been approved elsewhere for a while.
And would Brilacidin in this indication garner the same level of pharma disinterest? Wouldn't think so.
In any case IPIX is focusing solely at p2 OM and UP results, which look promising based on interim results, to land that deal.
My point is that they are sitting with an approved drug and no suitor, at least for the US market. Why? The drug has been approved elsewhere for a while.
And would Brilacidin in this indication garner the same level of pharma disinterest? Wouldn't think so.
In any case IPIX is focusing solely at p2 OM and UP results, which look promising based on interim results, to land that deal.
(0)
(0)
